Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
That’s why the company needs to demonstrate it can commercialise these products. The market hates uncertainty and that certainly seems to be the case as to whether the directors can bring these to fruitition. So IF news of a val401 commercialisation deal occurs then the market can be more confident that they are capable with the other compounds in future!
Hi Jinksy, it’s hard to say for sure. The last RNS quoted Dr Dilly as saying the peer review was in the process of ‘publication’. That leads me to believe it is probably in the final stages but it is anyone’s guess as to how long it will be until we see it. The quote does finalise with ‘...release of these further publications in due course’. I would hope we see them in the next 1-2 months max. Thanks, Geecee
I’m sure the peer review will provide an unbiased view as to whether this is an issue or not. We knew the patients weren’t healthy and they could have withdrawn for a multitude of reasons, on face value of this information alone you cannot say that it concludes the drug not being a success or is a success. IMO for this information to be the factor of why you invest or sell would be irrational but people are free to make decisions based on their own interpretations of the data. GLA, Geecee
I am enjoying the large detailed discussions. Big posts of research from both Chelsea and Sicilian have brought actual discussion back on the company and it’s progress rather than a keyboard war. Keep it up, good luck all!
Hi Valju, in GMs last proactive investor interview he did suggest it could be a consortium of investors. Meaning that it could be at late stages and still have multiple people at the table. Of course as you say could mean they are in early stages, we won’t know for sure until the deal RNS lands. Thanks, Geecee
I think the vague timelines given by the board are regulatory approval in 3-4 months although can take up to 6. This was in June/July (apologies I can’t remember which one). Then they would like to start phase III in early 2019, whether this means January or quarter 1 I’m not sure. Put that together to make what you will
Hi tozerk, it’s a gamble worth taking the way I see it as I’m on quite a low average. Can’t say that the past placings have been palatable but they are a means to an end. I’ll see this out until around March next year where if we haven’t heard of any news I’ll know the BoD can’t deliver but i think they’ll pull through. I’ve seen similar deals in different sectors take this amount of time and longer so I think it is plausible that they’ve been negotiating and ironing out the terms since the results, time will tell!
Hi Tozerk, Nicholas Slater had 18.5m shares when his holding was announced which equated to 4.54% of the company. The placing shares which came into effect shortly after put it to 4.11%. A 22.5m shareholding wouldn’t trigger a TR1 as would be 4.94%. Not saying it definitely is him as I’m sure everyone will draw their own conclusions as to whether this was him or sale of new issues shares. In any event we’ll know soon as either a TR1 re sale or if he kept 4.11% the dilution will make his holding sub 4% and will prompt a TR1. Cheers, Geecee
Supposedly they were given inside information which left them satisfied with the company’s direction. Not sure whether it was a publicity stunt or true. Either way I’m confident the meeting happened as I believe valirx confirmed it did but not sure what really came out of it to comfort or help PIs
Hi Tozerk, it’s based on reports. It’s a mob tool as any posts which are disagreed with in numbers are removed, it is a cost effective method for LSE I guess. Although both ramper and deramper posts are removed on this site, it’s not just an issue with one side! I honestly prefer to read both sides of the story as it certainly gives a wider perspective. ATB, Geecee